The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Epigenetic therapy of cancer: past, present and future
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Sarraf, S. A., & Stancheva, I. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.043 · Cited by 471
RetractedGhoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., & Jacob, S. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4727-4741.2005 · Cited by 431
RetractedJenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
Hypomethylation distinguishes genes of some human cancers from their normal counterparts
Feinberg, A. P., & Vogelstein, B. (1983) · Nature · doi:10.1038/301089a0 · Cited by 2,437
EUKARYOTIC CYTOSINE METHYLTRANSFERASES
Goll, M. G., & Bestor, T. H. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.010904.153721 · Cited by 2,063
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Cameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831
Self-citationSilverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Weber, M., Davies, J. J., Wittig, D., Oakeley, E. J., Haase, M., Lam, W. L., & Schübeler, D. (2005) · Nature Genetics · doi:10.1038/ng1598 · Cited by 1,754
Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin Assembly
Nakayama, J.-I., Rice, J. C., Strahl, B. D., Allis, C. D., & Grewal, S. I. S. (2001) · Science · doi:10.1126/science.1060118 · Cited by 1,739
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
Metzger, E., Wissmann, M., Yin, N., Müller, J. M., Schneider, R., Peters, A. H. F. M., Günther, T., Buettner, R., & Schüle, R. (2005) · Nature · doi:10.1038/nature04020 · Cited by 1,733
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
The power and the promise of DNA methylation markers
Laird, P. W. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1045 · Cited by 1,562
Comprehensive analysis of CpG islands in human chromosomes 21 and 22
Takai, D., & Jones, P. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052410099 · Cited by 1,514
Self-citationInduction of tumors in mice by genomic hypomethylation
Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., Leonhardt, H., & Jaenisch, R. (2003) · Science · doi:10.1126/science.1083558 · Cited by 1,499 · cited 1×
“The use of demethylating agents can aggravate the situation by further decreasing the level of methylation and activation of genes that are potentially deleterious — that is, oncogene”
BackgroundDnmt3L and the Establishment of Maternal Genomic Imprints
Bourc'his, D., Xu, G.-L., Lin, C.-S., Bollman, B., & Bestor, T. H. (2001) · Science · doi:10.1126/science.1065848 · Cited by 1,439
Chromosomal Instability and Tumors Promoted by DNA Hypomethylation
Eden, A., Gaudet, F., Waghmare, A., & Jaenisch, R. (2003) · Science · doi:10.1126/science.1083557 · Cited by 1,399
Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., & Horikawa, I. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-01-0033 · Cited by 1,364
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
Costello, J. F., Frühwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., Wright, F. A., Feramisco, J. D., Peltomäki, P., Lang, J. C., et al. (2000) · Nature Genetics · doi:10.1038/72785 · Cited by 1,357
Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L
Bourc'his, D., & Bestor, T. H. (2004) · Nature · doi:10.1038/nature02886 · Cited by 1,207
Multiple new phenotypes induced in and 3T3 cells treated with 5-azacytidine
Taylor, S. M., & Jones, P. A. (1979) · Cell · doi:10.1016/0092-8674(79)90317-9 · Cited by 1,100
Self-citationGlobal histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
Fang, M., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu, H., Welsh, W. J., & Yang, C. S. (2003) · PubMed · Cited by 1,049
Sodium butyrate inhibits histone deacetylation in cultured cells
Candido, E. (1978) · Cell · doi:10.1016/0092-8674(78)90305-7 · Cited by 1,036
A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin
Schotta, G., Lachner, M., Sarma, K., Ebert, A., Sengupta, R., Reuter, G., Reinberg, D., & Jenuwein, T. (2004) · Genes & Development · doi:10.1101/gad.300704 · Cited by 1,031
Hhal methyltransferase flips its target base out of the DNA helix
Klimasauskas, S., Kumar, S., Roberts, R. J., & Cheng, X. (1994) · Cell · doi:10.1016/0092-8674(94)90342-5 · Cited by 945
Histone methylation in transcriptional control
Kouzarides, T. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00287-3 · Cited by 908
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Rice, J. C., Briggs, S. D., Ueberheide, B., Barber, C. M., Shabanowitz, J., Hunt, D. F., Shinkai, Y., & Allis, C. D. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00479-9 · Cited by 825
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Schübeler, D., MacAlpine, D. M., Scalzo, D., Wirbelauer, C., Kooperberg, C., van Leeuwen, F., Gottschling, D. E., O'Neill, L. P., Turner, B. M., Delrow, J., et al. (2004) · Genes & Development · doi:10.1101/gad.1198204 · Cited by 796
The key to development: interpreting the histone code?
Margueron, R., Trojer, P., & Reinberg, D. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.01.005 · Cited by 749
Suppression of intestinal neoplasia by DNA hypomethylation
Laird, P. W., Jackson-Grusby, L., Fazeli, A., Dickinson, S. L., Edward Jung, W., Li, E., Weinberg, R. A., & Jaenisch, R. (1995) · Cell · doi:10.1016/0092-8674(95)90329-1 · Cited by 710
Vakoc, C. R., Mandat, S. A., Olenchock, B. A., & Blobel, G. A. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.011 · Cited by 696
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
The effect of sodium butyrate on histone modification
Sealy, L. (1978) · Cell · doi:10.1016/0092-8674(78)90306-9 · Cited by 686
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
Lo, W.-S., Trievel, R. C., Rojas, J. R., Duggan, L., Hsu, J.-Y., Allis, C. D., Marmorstein, R., & Berger, S. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80257-9 · Cited by 577
García-Cao, M., O'Sullivan, R., Peters, A. H. F. M., Jenuwein, T., & Blasco, M. A. (2004) · Nature Genetics · doi:10.1038/ng1278 · Cited by 557
Brueckner, B., Garcia Boy, R., Siedlecki, P., Musch, T., Kliem, H. C., Zielenkiewicz, P., Suhai, S., Wiessler, M., & Lyko, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2957 · Cited by 545
A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response
Masumoto, H., Hawke, D., Kobayashi, R., & Verreault, A. (2005) · Nature · doi:10.1038/nature03714 · Cited by 544
Peart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine
Cheng, J. C., Matsen, C. B., Gonzales, F. A., Ye, W., Greer, S., Marquez, V. E., Jones, P. A., & Selker, E. U. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.399 · Cited by 535
Self-citationThe histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523 · cited 1×
“Valproic acid has been shown to inhibit HDAC1 and HDAC2 by decreasing catalytic activity and proteasomal degradation, respectivel”
BackgroundCovalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine.
Santi, D. V., Norment, A., & Garrett, C. E. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.22.6993 · Cited by 518
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Bannister, A. J., & Kouzarides, T. (2005) · Nature · doi:10.1038/nature04048 · Cited by 502
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Liang, G., Lin, J. C. Y., Wei, V., Yoo, C., Cheng, J. C., Nguyen, C. T., Weisenberger, D. J., Egger, G., Takai, D., Gonzales, F. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401866101 · Cited by 484
Self-citationPiekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L.-S., Lee, S.-L., Leighton, J. K., Patel, H., Rahman, A., Sridhara, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2135 · Cited by 423
5-Methylcytosine, Gene Regulation, and Cancer
(1983) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60678-8 · Cited by 422
Kinetic and catalytic mechanism of HhaI methyltransferase.
Wu, J. C., & Santi, D. V. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61263-3 · Cited by 420
Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity.
Cornacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S., & Richardson, B. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.7.2197 · Cited by 420
Kornblith, A. B., Herndon, J. E., Silverman, L. R., Demakos, E. P., Odchimar-Reissig, R., Holland, J. F., Powell, B. L., DeCastro, C., Ellerton, J., Larson, R. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.044 · Cited by 419
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412
On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs
Santi, D. V., Garrett, C. E., & Barr, P. J. (1983) · Cell · doi:10.1016/0092-8674(83)90327-6 · Cited by 401
Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 398
Zhou, L., Cheng, X., Connolly, B. A., Dickman, M. J., Hurd, P. J., & Hornby, D. P. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00676-9 · Cited by 362
The role of DNA methylation in setting up chromatin structure during development
Hashimshony, T., Zhang, J., Keshet, I., Bustin, M., & Cedar, H. (2003) · Nature Genetics · doi:10.1038/ng1158 · Cited by 359
Histone deacetylase inhibitors
Monneret, C. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.10.001 · Cited by 338
Preferential response of cancer cells to zebularine
Cheng, J. C., Yoo, C. B., Weisenberger, D. J., Chuang, J., Wozniak, C., Liang, G., Marquez, V. E., Greer, S., Orntoft, T. F., Thykjaer, T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.023 · Cited by 319
Self-citationProcaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.
Villar‐Garea, A., Fraga, M. F., Espada, J., & Esteller, M. (2003) · PubMed · Cited by 316
(2003) · PubMed · Cited by 313
Piña, I. C., Gautschi, J. T., Wang, G.-Y.-S., Sanders, M. L., Schmitz, F. J., France, D., Cornell-Kennon, S., Sambucetti, L. C., Remiszewski, S. W., Perez, L. B., et al. (2003) · The Journal of Organic Chemistry · doi:10.1021/jo034248t · Cited by 311
Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9
Mutskov, V., & Felsenfeld, G. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600013 · Cited by 296
Issa, J.-P. J., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G., & Kantarjian, H. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.981 · Cited by 288
Unsafe SETs: histone lysine methyltransferases and cancer
Schneider, R., Bannister, A. J., & Kouzarides, T. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02141-2 · Cited by 287
Chen, L.-F., & Greene, W. C. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0469-0 · Cited by 275
Causes and consequences of DNA hypomethylation in human cancer
Hoffmann, M. J., & Schulz, W. A. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-036 · Cited by 252
Direct identification of the active-site nucleophile in a DNA (cytosine-5)-methyltransferase
Chen, L., MacMillan, A. M., Chang, W., Ezaz-Nikpay, K., Lane, W. S., & Verdine, G. L. (1991) · Biochemistry · doi:10.1021/bi00110a002 · Cited by 249
Qiu, L., Burgess, A., Fairlie, D. P., Leonard, H., Parsons, P. G., & Gabrielli, B. G. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.6.2069 · Cited by 249
Epigenetic regulation of 11β-hydroxysteroid dehydrogenase type 2 expression
Alikhani-Koopaei, R., Fouladkou, F., Frey, F. J., & Frey, B. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421647 · Cited by 248
Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5429-5444.2005 · Cited by 245
Duan, H., Heckman, C. A., & Boxer, L. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1608-1619.2005 · Cited by 242
Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo
Michaelis, M., Michaelis, U. R., Fleming, I., Suhan, T., Cinatl, J., Blaheta, R. A., Hoffmann, K., Kotchetkov, R., Busse, R., Nau, H., et al. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.520 · Cited by 227
Fujita, N., Takebayashi, S.-I., Okumura, K., Kudo, S., Chiba, T., Saya, H., & Nakao, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6415 · Cited by 214
Chuang, J. C., Yoo, C. B., Kwan, J. M., Li, T. W. H., Liang, G., Yang, A. S., & Jones, P. A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0172 · Cited by 210
Self-citationMomparler, R. L., Bouffard, D. Y., Momparler, L. F., Dionne, J., B??langer, K., & Ayoub, J. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199704000-00008 · Cited by 210
Camphausen, K., Burgan, W., Cerra, M., Oswald, K. A., Trepel, J. B., Lee, M.-J., & Tofilon, P. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2630 · Cited by 209
Segura-Pacheco, B. A., Trejo‐Becerril, C., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Mariscal, I., Chavez, A., Acuña, C., Salazar, A. M., Lizano, M., & Dueñas‐González, A. (2003) · PubMed · Cited by 206
Liang, G., Gonzales, F. A., Jones, P. A., Orntoft, T. F., & Thykjær, T. (2002) · PubMed · Cited by 205
Self-citationA phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Zhaoyang Li, M., et al. (2002) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2002.01039.x · Cited by 204
Zebularine: a new drug for epigenetic therapy
Yoo, C. B., Cheng, J. C., & Jones, P. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320910 · Cited by 191
Self-citationGius, D., Cui, H., Bradbury, C. M., Cook, J., Smart, D. K., Zhao, S., Young, L., Brandenburg, S. A., Hu, Y., Bisht, K. S., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.029 · Cited by 181
Lin, X., Asgari, K., PUTZI, M. J., Gage, W. R., Yu, X., Cornblatt, B. S., Kumar, A., Piantadosi, S., DeWeese, T. L., Marzo, A. M. D., et al. (2001) · PubMed · Cited by 180
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis
Chen, W., Cooper, T. K., Zahnow, C. A., Overholtzer, M., Zhao, Z., Ladanyi, M., Karp, J. E., Gokgoz, N., Wunder, J. S., Andrulis, I. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.030 · Cited by 165
Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
Yang, H., Hoshino, K., Sanchez-Gonzalez, B., Kantarjian, H., & Garcia-Manero, G. (2005) · Leukemia Research · doi:10.1016/j.leukres.2004.11.022 · Cited by 163
A Crack in Histone Lysine Methylation
Kubicek, S., & Jenuwein, T. (2004) · Cell · doi:10.1016/j.cell.2004.12.006 · Cited by 158
Zambrano, P., Segura-Pacheco, B. A., Pérez‐Cárdenas, E., Cetina, L., Vázquez, A. L. R., Taja‐Chayeb, L., Chávez-Blanco, A. D., Ángeles, E., Cabrera, G., Sandoval, K., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-44 · Cited by 156
Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes
Gibbons, R. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi106 · Cited by 155
Samlowski, W. E., Leachman, S. A., Wade, M. L., Cassidy, P. B., Porter-Gill, P. A., Busby, L. T., Wheeler, R. H., Boucher, K. M., Fitzpatrick, F. A., Jones, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.118 · Cited by 141
Shetty, S., Graham, B. A., Brown, J. G., Hu, X., Vegh-Yarema, N., Harding, G. A., Paul, J. T., & Gibson, S. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5404-5416.2005 · Cited by 139
Trapped in action: direct visualization of DNA methyltransferase activity in living cells
Schermelleh, L., Spada, F., Easwaran, H., Zolghadr, K., Margot, J. B., Cardoso, M. C., & Leonhardt, H. (2005) · Nature Methods · doi:10.1038/nmeth794 · Cited by 138
Chronic Oral Administration of CI-994: A Phase I Study
Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L. E., Zalupski, M. M., Radulovic, L. L., Valdivieso, M., & LoRusso, P. M. (2001) · Investigational New Drugs · doi:10.1023/a:1006489328324 · Cited by 136
In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation
Perini, G., Diolaiti, D., Porro, A., & Valle, G. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409097102 · Cited by 136
Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice.
Šorm, F., & Veselý, J. (1968) · PubMed · Cited by 134
Remiszewski, S., Sambucetti, L. C., Bair, K. W., Bontempo, J., Cesarz, D., Chandramouli, N., Chen, R., Cheung, M., Cornell-Kennon, S., Dean, K., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030235w · Cited by 130
Joseph, J., Mudduluru, G., Antony, S., Vashistha, S., Ajitkumar, P., & Somasundaram, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207852 · Cited by 127
Schwartsmann, G., Schünemann, H. J., Gorini, C., Filho, A. F. F., Garbino, C., Sabini, G., Musé, I., Leone, L. P. D., & Mans, D. R. A. (2000) · Investigational New Drugs · doi:10.1023/a:1006388031954 · Cited by 111
Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes
Hendrich, B., Abbott, C. M., McQueen, H. A., Chambers, D. M., Cross, S. H., & Bird, A. P. (1999) · Mammalian Genome · doi:10.1007/s003359901112 · Cited by 110
Phase I trial of continuous infusion 5-aza-2′-deoxycytidine
Aparicio, A. M., Eads, C. A., Leong, L., Laird, P. W., Newman, E. M., Synold, T. W., Baker, S. D., Zhao, M., & Weber, J. S. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0563-y · Cited by 109
Rudek, M. A., Zhao, M., He, P., Hartke, C., Gilbert, J., Gore, S. D., Carducci, M. A., & Baker, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.450 · Cited by 109
Pauer, L., Olivares, J., Cunningham, C. C., Williams, A., Grove, W. R., Kraker, A. J., Olson, S. C., & Nemunaitis, J. J. (2004) · Cancer Investigation · doi:10.1081/cnv-200039852 · Cited by 106
High-performance Liquid Chromatographic Analysis of Chemical Stability of 5-aza-2′-Deoxycytidine
Lin, K.-T., Momparlerm, R. L., & Rivard, G. E. (1981) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600701112 · Cited by 102
Synthesis of a 2-deoxy-D-ribofuranosyl-5-azacytosine
Pliml, J., & Šorm, F. (1964) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc19642576 · Cited by 101
Lalibert�, J., Márquez, V. E., & Momparler, R. L. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686478 · Cited by 97
Holleran, J. L., Parise, R. A., Joseph, E., Eiseman, J. L., Covey, J. M., Glaze, E. R., Lyubimov, A. V., Chen, Y.-F., D’Argenio, D. Z., & Egorin, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2406 · Cited by 97
Davis, A. J., Gelmon, K. A., Siu, L. L., Moore, M. J., Britten, C. D., Mistry, N., Klamut, H. J., D’Aloisio, S., MacLean, M., Wainman, N., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1022976528441 · Cited by 92
Zagonel, V., Re, G. L., Marotta, G., Babare, R., Sardeo, G., Gattei, V., Angelis, V. D., Monfardini, S., & Pinto, A. (1993) · PubMed · Cited by 92
Rocchi, P., Tonelli, R., Camerin, C., Purgato, S., Fronza, R., Bianucci, F., Guerra, F., Pession, A., & Ferreri, A. M. (2005) · Oncology Reports · doi:10.3892/or.13.6.1139 · Cited by 89
The Discovery of NVP-LAQ824: From Concept to Clinic
Remiszewski, S. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456675 · Cited by 88
Raffoux, E., Chaı̈bi, P., Dombret, H., & Degos, L. (2005) · PubMed · Cited by 87
Pohlmann, P. R., Leone, L. P. D., Cancella, A., Caldas, A. P. F., Lago, L. D., Campos, O., Monego, E., Rivoire, W. A., & Schwartsmann, G. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200210000-00015 · Cited by 87
van de Mark, K., Chen, J. S., Steliou, K., Perrine, S. P., & Faller, D. V. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10205 · Cited by 83
Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase
Kim, C. H., Márquez, V. E., Mao, D. T., Haines, D. R., & McCormack, J. J. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00158a009 · Cited by 82
Whetstine, J. R., Cerón, J., Ladd, B., Dufourcq, P., Reinke, V., & Shi, Y. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.006 · Cited by 76
Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogs
Driscoll, J. S., Márquez, V. E., Plowman, J., Liu, P. S., Kelley, J. A., & Barchi, J. J. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00115a017 · Cited by 76
Wang, X., Qian, D. Z., Ren, M., Kato, Y., Wei, Y., Zhang, L., Fansler, Z. B., Clark, D., Nakanishi, O., & Пили, Р. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1092 · Cited by 75
Herranz, M., Martín‐Caballero, J., Fraga, M. F., Ruı́z-Cabello, J., Flores, J. M., Desco, M., Márquez, V. E., & Esteller, M. (2005) · Blood · doi:10.1182/blood-2005-05-2033 · Cited by 72
Undevia, S. D., Kindler, H. L., Janisch, L. A., Olson, S. C., Schilsky, R. L., Vogelzang, N. J., Kimmel, K. A., Macek, T. A., & Ratain, M. J. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh438 · Cited by 71
Cyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylases
Nishino, N., Jose, B., Okamura, S., Ebisusaki, S., Kato, T., Sumida, Y., & Yoshida, M. (2003) · Organic Letters · doi:10.1021/ol036098e · Cited by 67
Modulation of angiogenesis-related protein synthesis by valproic acid
Zgouras, D., Becker, U., Loitsch, S. M., & Stein, J. M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.105 · Cited by 65
Jose, B., Oniki, Y., Kato, T., Nishino, N., Sumida, Y., & Yoshida, M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.016 · Cited by 65
Singh, S. B., Zink, D. L., Liesch, J. M., Dombrowski, A. W., Darkin‐Rattray, S. J., Schmatz, D. M., & GOETZ, M. A. (2001) · Organic Letters · doi:10.1021/ol016240g · Cited by 57
Perrine, S. P., Olivieri, N. F., Faller, D. V., Vichinsky, E. P., Dover, G., & Ginder, G. D. (1994) · PubMed · Cited by 56
Phase II study of 5-azacytidine in solid tumors.
Weiss, A. J., Metter, G. E., Nealon, T. F., et al. (1977) · PubMed · Cited by 49
Beisler, J. A., Abbasi, M. M., Kelley, J. A., & Driscoll, J. S. (1977) · Journal of Medicinal Chemistry · doi:10.1021/jm00216a013 · Cited by 48
Lübbert, M., Daskalakis, M., Kunzmann, R., Engelhardt, M. M., Guo, Y., & Wijermans, P. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.04.002 · Cited by 33
Nishino, N., Yoshikawa, D., Watanabe, L. A., Kato, T., Jose, B., Komatsu, Y., Sumida, Y., & Yoshida, M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.03.018 · Cited by 33
A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
Curt, G. A., Kelley, J. A., Fine, R. L., Huguenin, P. N., Roth, J. S., Batist, G., Jenkins, J., & Collins, J. M. (1985) · PubMed · Cited by 33
Eidinoff, M. L., Rich, M. A., & Perez, A. G. (1959) · PubMed · Cited by 24
Presant, C. A., Coulter, D., Valeriote, F. A., & Vietti Teresa, J. (1981) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/66.6.1151 · Cited by 8
In living color: DNA methyltransferase caught in the act
Schuebel, K. E., & Baylin, S. B. (2005) · Nature Methods · doi:10.1038/nmeth1005-736 · Cited by 7
Cited by
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Self-citationSharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637
Self-citationEnvironmental epigenomics and disease susceptibility
Jirtle, R. L., & Skinner, M. K. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2045 · Cited by 2,492
Epigenetics: A landscape takes shape
Goldberg, A. D., Allis, C. D., & Bernstein, E. (2007) · Cell · doi:10.1016/j.cell.2007.02.006 · Cited by 2,466
Metadata
- Authors
- Yoo, C. B., & Jones, P. A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-01
- Volume
- 5
- Issue
- 1
- Pages
- 37-50
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2009121506
- Cited by
- 1,289
- References
- 144
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.